SILEXION THERAPEUTICS CORP (SLXN) Stock Overview
USA - NASDAQ:SLXN - KYG1281K1224 - Common Stock
SLXN Key Statistics, Chart & Performance
The current stock price of SLXN is 4.07 USD. In the past month the price decreased by -44.7%. In the past year, price decreased by -97.01%.
SLXN Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 20.62 | 385.71B | ||
| AMGN | AMGEN INC | 12.67 | 148.80B | ||
| GILD | GILEAD SCIENCES INC | 14.8 | 142.13B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.29 | 101.15B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 61.07B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.27 | 59.35B | ||
| ARGX | ARGENX SE - ADR | 81.59 | 46.29B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.67 | 38.56B | ||
| INSM | INSMED INC | N/A | 30.85B | ||
| BNTX | BIONTECH SE-ADR | N/A | 23.26B | ||
| NTRA | NATERA INC | N/A | 23.13B | ||
| BIIB | BIOGEN INC | 9.05 | 21.24B |
Related stock screener links
About SLXN
Company Profile
Silexion Therapeutics Corp is a IL-based company operating in Biotechnology industry. Silexion Therapeutics Corp is an Israel-based oncology-focused biotechnology company. The firm is engaged in development of treatments for unsatisfactorily treated solid tumor cancers, which have the mutated KRAS oncogene. The KRAS gene is an oncogene that is involved in regulation of cell division as a result of its ability to relay external signals to the cell nucleus. Based on its research of refractory solid tumor cancers, it is developing a platform focused on the silencing of the KRAS oncogene using ribonucleic acid (RNA)-interference therapeutics. Its lead product candidate, SIL-204B, consists of locally administered small interfering RNAs (siRNA), in an extended-release formulation, as a preferred treatment of locally advanced pancreatic cancer patients, in combination with standard-of-care chemotherapy. Its clinical-stage pipeline is focused on treatment for pancreatic cancer (PC) tumors bearing the KRAS G12D or KRAS G12V mutations where metastases have not been detected.
Company Info
SILEXION THERAPEUTICS CORP
12 Abba Hillel Road
Ramat Gan IL
Employees: 11
Phone: 97286286005
SILEXION THERAPEUTICS CORP / SLXN FAQ
What is the stock price of SILEXION THERAPEUTICS CORP today?
The current stock price of SLXN is 4.07 USD. The price decreased by -17.44% in the last trading session.
What is the ticker symbol for SILEXION THERAPEUTICS CORP stock?
The exchange symbol of SILEXION THERAPEUTICS CORP is SLXN and it is listed on the Nasdaq exchange.
On which exchange is SLXN stock listed?
SLXN stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for SILEXION THERAPEUTICS CORP stock?
7 analysts have analysed SLXN and the average price target is 24.48 USD. This implies a price increase of 501.47% is expected in the next year compared to the current price of 4.07. Check the SILEXION THERAPEUTICS CORP stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is SILEXION THERAPEUTICS CORP worth?
SILEXION THERAPEUTICS CORP (SLXN) has a market capitalization of 4.27M USD. This makes SLXN a Nano Cap stock.
How many employees does SILEXION THERAPEUTICS CORP have?
SILEXION THERAPEUTICS CORP (SLXN) currently has 11 employees.
What are the support and resistance levels for SILEXION THERAPEUTICS CORP (SLXN) stock?
SILEXION THERAPEUTICS CORP (SLXN) has a resistance level at 7.28. Check the full technical report for a detailed analysis of SLXN support and resistance levels.
Should I buy SILEXION THERAPEUTICS CORP (SLXN) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of SLXN, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of SLXN, evaluating the profitability, health, valuation and growth aspects
- SILEXION THERAPEUTICS CORP (SLXN) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- SILEXION THERAPEUTICS CORP (SLXN) Sales and EPS estimates to see what analysts future expectations are.
- SILEXION THERAPEUTICS CORP (SLXN) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- SILEXION THERAPEUTICS CORP (SLXN) Insider and Institutional Ownership to learn about the owners and their transactions.
- SILEXION THERAPEUTICS CORP (SLXN) Stock Chart to make your own analysis
- SILEXION THERAPEUTICS CORP (SLXN) Latest news and press-releases to stay up to date.
Does SILEXION THERAPEUTICS CORP (SLXN) stock pay dividends?
SLXN does not pay a dividend.
What is the Price/Earnings (PE) ratio of SILEXION THERAPEUTICS CORP (SLXN)?
SILEXION THERAPEUTICS CORP (SLXN) does not have a PE ratio as the earnings reported over the last twelve months were negative (-350.07).
SLXN Technical Analysis
SLXN Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to SLXN. SLXN may be in some trouble as it scores bad on both profitability and health.
SLXN Financial Highlights
Over the last trailing twelve months SLXN reported a non-GAAP Earnings per Share(EPS) of -350.07. The EPS decreased by -3004.48% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -307.83% | ||
| ROE | -14870.83% | ||
| Debt/Equity | 26.58 |
SLXN Forecast & Estimates
7 analysts have analysed SLXN and the average price target is 24.48 USD. This implies a price increase of 501.47% is expected in the next year compared to the current price of 4.07.